Healthcare Services

Advancements in inhaled therapies are shaping the emphysema treatment market

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Emphysema Market Between 2026 And 2030?

The emphysema market size has shown consistent growth in recent years. It is anticipated to expand from $4.94 billion in 2025 to $5.17 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.6%. In the past, this market’s expansion was primarily driven by factors such as smoking prevalence, exposure to air pollution, an aging population, increased respiratory disease awareness, and the broadening of healthcare access.

The emphysema market size is anticipated to demonstrate consistent growth over the coming years. By 2030, it is projected to reach a value of $6.19 billion, exhibiting a compound annual growth rate (CAGR) of 4.6%. This expansion during the forecast period can be attributed to factors such as early screening initiatives, the availability of home-based respiratory care, the uptake of advanced diagnostic methods, a heightened focus on managing chronic diseases, and stricter environmental health regulations. Significant trends influencing the forecast period encompass an increasing prevalence of chronic respiratory conditions, a greater emphasis on the early detection of COPD, the proliferation of long-term oxygen therapy, the expansion of pulmonary rehabilitation programs, and a strong focus on smoking cessation interventions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

What Key Drivers Are Fueling The Growth Of The Emphysema Market?

The anticipated expansion of the emphysema market is linked to the rising occurrence of respiratory infections. These infections target various parts of the respiratory system, such as the sinuses, throat, airways, and lungs. Factors contributing to the rise in respiratory infections include pollution, climate change, antimicrobial resistance, urbanization, and the emergence of new pathogens. The progression of emphysema is accelerated by respiratory infections through the induction of inflammation, damage to tissues, and heightened obstruction of airways, thereby deteriorating lung function. An example illustrates this trend: data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that in November 2024, the U.S. recorded 9,633 tuberculosis (TB) cases in 2023. This represented a 15.6% increase from the 8,332 cases reported in 2022, with the incidence rate climbing 15.0% from 2.5 to 2.9 per 100,000 persons. Consequently, the expanding occurrence of respiratory infections serves as a primary driver for the growth of the emphysema market.

What Are The Different Segment Types In The Emphysema Market Segment Breakdown?

The emphysema market covered in this report is segmented –

1) By Type: Centrilobular, Panlobular

2) By Treatment: Medication, Therapy, Surgery, Other Treatments

3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis

4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications

5) By End-User: Hospitals And Clinics, Surgical Center, Other End-Users

Subsegments:

1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema

2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema

What Trends Are Influencing The Emphysema Market?

Leading companies in the emphysema market are prioritizing the development of novel medical solutions, such as inhaled dual inhibitors of phosphodiesterase 3 and phosphodiesterase 4. These efforts aim to offer patients sophisticated therapies designed to enhance lung function, alleviate inflammation, and improve overall disease management, ultimately promoting superior respiratory health and quality of life. An inhaled dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4 functions by targeting and inhibiting both phosphodiesterase enzymes within the lungs. This action facilitates airway relaxation and reduces inflammatory responses, thereby improving breathing for individuals with conditions such as chronic obstructive pulmonary disease. A notable example is the introduction in June 2024 by Verona Pharma plc, a UK-based pharma company, of Ohtuvayre (ensifentrine). This product stands as the first inhaled dual PDE3 and PDE4 inhibitor to gain approval from the Food and Drug Administration, a US-based federal agency, for the ongoing treatment of chronic obstructive pulmonary diseases including emphysema. This launch signifies the first new inhaled therapy available in over 20 years. This medication, which possesses both bronchodilator and anti-inflammatory properties, will be distributed via specialty pharmacies.

Who Are The Well-Known Companies In The Emphysema Market?

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., ResMed Inc., Chiesi Farmaceutici S.p.A., VIDA Diagnostics Inc., Pulmonx Corporation, F Hoffmann-La Roche Ltd, Cipla Limited, Abbott Laboratories, Astellas Pharma Inc., Covis Pharma Group, FindAir Sp z o o, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Lifesciences, Theravance Biopharma Inc, Pulmatrix Inc, Genentech, Dimerix Ltd, InMed Pharmaceuticals Inc.

Get The Full Emphysema Market Report:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Where Is The Emphysema Market Primarily Concentrated By Region?

North America was the largest region in the emphysema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Emphysema Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Browse Through More Reports Similar to the Global Emphysema Market 2026, By The Business Research Company

Pulmonary Embolism Market Report 2026

https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report

Anaphylaxis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

Interstitial Lung Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795